Glenmark Pharmaceuticals today said in a BSE filing that it has received final approval from the US FDA to sell oral contraceptive drospirenone and ethinyl estradiol tablets in the US market. The product is a generic version Bayer’s Yaz tablets.
Glenmark said it plans to commence shipping of drospirenone and ethinyl estradiol tablets immediately. Citing IMS Health sales data, the company said for the 12 months period ending June, “the Yaz market achieved annual sales of approximately $170.1 million”.